BridgeBio’s week just went from great to superb, as it reports a second positive topline result in a pivotal trial of a late-stage pipeline drug.
Scribing startups are reinventing themselves beyond notetaking as shakeout nears
AI scribes have been one of the hottest areas in healthcare, raising $1.6 billion so far this year alone. But as health IT giants like Epic roll out their own versions …
Specialty meds lift GSK’s outlook in Walmsley’s swan song
Emma Walmsley’s last set of financial results as GSK’s chief executive has gone swimmingly, allowing the company to raise its 2025 forecasts.
Weight loss drugs could be cost-effective even at higher prices, ICER says
The mounting evidence that Novo Nordisk’s and Eli Lilly’s blockbuster weight loss drugs provide significant benefits to patients supports even higher prices for the drugs, a major drug pricing watchdog said on Tuesday, in one …
From Power Users to Protective Stewards: How to Tune Security Training for Specialized Employees
How the best security training programs build strong security culture by focusing on high-risk groups like developers, executives, finance pros and more.
GSK trims pipeline, bumps guidance in Emma Walmsley’s last earnings report
GSK made some pipeline cuts and raised expectations for profit growth this year as it reported its final set of earnings under outgoing CEO Emma Walmsley. The UK drugmaker axed several programs that were originally …
Falling flu vaccine sales in US stall CSL’s Seqirus spinout
CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.
BridgeBio gets another Phase 3 rare disease win, this time in thyroid disorder
BridgeBio declared another Phase 3 rare disease win Wednesday morning on the heels of a late-stage success earlier this week. The biotech’s oral drug encaleret hit the primary endpoint for a genetic thyroid disorder called …
The AI Hype Index: Data centers’ neighbors are pivoting to power blackouts
Separating AI reality from hyped-up fiction isn’t always easy. That’s why we’ve created the AI Hype Index—a simple, at-a-glance summary of everything you need to know about the state of the industry. Just about all businesses these days seem to be pivoting to AI, even when they don’t seem to know exactly why they’re investing […]
WuXi AppTec to shutter Texas-based clinical research business
WuXi AppTec is closing down its contract research organization in Austin, TX, by the end of the year, a company spokesperson told Endpoints News. The move is part of its goal to “sharpen” its focus …